Sar1b transgenic male mice are more susceptible to high-fat diet-induced obesity, insulin insensitivity and intestinal chylomicron overproduction

Journal of Nutritional Biochemistry

Volumn 25, Issue 5, 2014, Pages 540-548

  Levy, Emile ^a,b,c   Spahis, Schohraya ^a,b   Garofalo, Carole ^a   Marcil, Valérie ^d   Montoudis, Alain ^a   Sinnet, Daniel ^b   Sanchez, Rocio ^a   Peretti, Noel ^e   Beaulieu, Jean François ^c   Sane, Alain ^a  

^a Research Center   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Chylomicron production; Fat absorption; Fatty acids; Insulin resistance; Lipids; Sar1B GTPase

Indexed keywords

CHOLESTEROL; CHYLOMICRON; GLUCOSE; GUANOSINE TRIPHOSPHATASE; OROTIC ACID; PHOSPHOLIPID; PROTEIN SAR1B; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; FATTY ACID; LIPID; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; SAR1B PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; CALORIC INTAKE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN SENSITIVITY; INSULINEMIA; INTESTINE ABSORPTION; LIPID ABSORPTION; LIPID COMPOSITION; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN SECRETION; MALE; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; ORGAN WEIGHT; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WILD TYPE; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY WEIGHT; EATING; GENE EXPRESSION REGULATION; GENETICS; INSULIN RESISTANCE; INTESTINE; METABOLISM; ORGAN SIZE;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; BODY WEIGHT; CHYLOMICRONS; DIET, HIGH-FAT; EATING; FATTY ACIDS; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; INTESTINAL ABSORPTION; INTESTINES; LIPID METABOLISM; LIPIDS; MALE; MICE, TRANSGENIC; MONOMERIC GTP-BINDING PROTEINS; OBESITY; ORGAN SIZE; TRIGLYCERIDES;

EID: 84897961601     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.01.004     Document Type: Article

References (37)

1. Xiao C., Lewis G.F. Regulation of chylomicron production in humans. Biochim Biophys Acta 1821, 2012:736-746.
2. Pan X., Hussain M.M. Gut triglyceride production. Biochim Biophys Acta 1821, 2012:727-735.
3. Kindel T., Lee D.M., Tso P. The mechanism of the formation and secretion of chylomicrons. Atheroscler Suppl 2010, 11:11-16.
4. Levy E., Stan S., Delvin E., Menard D., Shoulders C., Garofalo C., et al. Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J Biol Chem 2002, 277:16470-16477.
5. Levy E., Stan S., Garofalo C., Delvin E.E., Seidman E.G., Menard D. Immunolocalization, ontogeny, and regulation of microsomal triglyceride transfer protein in human fetal intestine. Am J Physiol Gastrointest Liver Physiol 2001, 280:G563-G571.
6. Slight I., Bendayan M., Malo C., Delvin E., Lambert M., Levy E. Identification of microsomal triglyceride transfer protein in intestinal brush-border membrane. Exp Cell Res 2004, 300:11-22.
7. Raabe M., Veniant M.M., Sullivan M.A., Zlot C.H., Bjorkegren J., Nielsen L.B., et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 1999, 103:1287-1298.
8. Wetterau J.R., Gregg R.E., Harrity T.W., Arbeeny C., Cap M., Connolly F., et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998, 282:751-754.
9. Jones B., Jones E.L., Bonney S.A., Patel H.N., Mensenkamp A.R., Eichenbaum-Voline S., et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet 2003, 34:29-31.
10. Siddiqi S., Mansbach C.M. Phosphorylation of Sar1b protein releases liver fatty acid-binding protein from multiprotein complex in intestinal cytosol enabling it to bind to endoplasmic reticulum (ER) and bud the pre-chylomicron transport vesicle. J Biol Chem 2012, 287:10178-10188.
11. Peretti N., Roy C.C., Sassolas A., Deslandres C., Drouin E., Rasquin A., et al. Chylomicron retention disease: a long term study of two cohorts. Mol Genet Metab 2009, 97:136-142.
12. Peretti N., Sassolas A., Roy C.C., Deslandres C., Charcosset M., Castagnetti J., et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis 2010, 5:24.
13. Roy C.C., Levy E., Green P.H., Sniderman A., Letarte J., Buts J.P., et al. Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B Chylomicron retention disease. Gastroenterology 1987, 92:390-399.
14. Levy E., Marcel Y., Deckelbaum R.J., Milne R., Lepage G., Seidman E., et al. Intestinal apoB synthesis, lipids, and lipoproteins in chylomicron retention disease. J Lipid Res 1987, 28:1263-1274.
15. Silvain M., Bligny D., Aparicio T., Laforet P., Grodet A., Peretti N., et al. Anderson's disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities. Clin Genet 2008, 74:546-552.
16. Levy E., Harmel E., Laville M., Sanchez R., Emonnot L., Sinnett D., et al. Expression of Sar1b enhances chylomicron assembly and key components of the coat protein complex II system driving vesicle budding. Arterioscler Thromb Vasc Biol 2011, 31:2692-2699.
17. Kisseberth W.C., Brettingen N.T., Lohse J.K., Sandgren E.P. Ubiquitous expression of marker transgenes in mice and rats. Dev Biol 1999, 214:128-138.
18. Spahis S., Vanasse M., Belanger S.A., Ghadirian P., Grenier E., Levy E. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2008, 79:47-53.
19. Levy E., Menard D., Delvin E., Stan S., Mitchell G., Lambert M., et al. The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants. J Biol Chem 2001, 276:39679-39684.
20. Levy E., Thibault L., Menard D. Intestinal lipids and lipoproteins in the human fetus: modulation by epidermal growth factor. J Lipid Res 1992, 33:1607-1617.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
22. Lee M.C., Miller E.A., Goldberg J., Orci L., Schekman R. Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol 2004, 20:87-123.
23. Jensen D., Schekman R. COPII-mediated vesicle formation at a glance. J Cell Sci 2011, 124:1-4.
24. Gurkan C., Stagg S.M., Lapointe P., Balch W.E. The COPII cage: unifying principles of vesicle coat assembly. Nat Rev Mol Cell Biol 2006, 7:727-738.
25. Lee M.C., Miller E.A. Molecular mechanisms of COPII vesicle formation. Semin Cell Dev Biol 2007, 18:424-434.
26. Sato K., Nakano A. Mechanisms of COPII vesicle formation and protein sorting. FEBS Lett 2007, 581:2076-2082.
27. Okada T., Miyashita M., Fukuhara J., Sugitani M., Ueno T., Samson-Bouma M.E., et al. Anderson's disease/chylomicron retention disease in a Japanese patient with uniparental disomy 7 and a normal SAR1B gene protein coding sequence. Orphanet J Rare Dis 2011, 6:78.
28. Siddiqi S.A., Gorelick F.S., Mahan J.T., Mansbach C.M. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J Cell Sci 2003, 116:415-427.
29. Rajala M.W., Scherer P.E. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
30. Qureshi K., Abrams G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007, 13:3540-3553.
31. Bouloumie A., Curat C.A., Sengenes C., Lolmede K., Miranville A., Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005, 8:347-354.
32. Boden G., Chen X., Ruiz J., White J.V., Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994, 93:2438-2446.
33. Kleiner S., Mepani R.J., Laznik D., Ye L., Jurczak M.J., Jornayvaz F.R., et al. Development of insulin resistance in mice lacking PGC-1alpha in adipose tissues. Proc Natl Acad Sci U S A 2012, 109:9635-9640.
34. Nyman L.R., Tian L., Hamm D.A., Schoeb T.R., Gower B.A., Nagy T.R., et al. Long term effects of high fat or high carbohydrate diets on glucose tolerance in mice with heterozygous carnitine palmitoyltransferase-1a (CPT-1a) deficiency: diet influences on CPT1a deficient mice. Nutr Diabetes. 2011, 1:e14.
35. Ciapaite J., van den Broek N.M., Te B.H., Nicolay K., Jeneson J.A., Houten S.M., et al. Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats. Biochim Biophys Acta 1811, 2011:441-451.
36. Kim S., Sohn I., Ahn J.I., Lee K.H., Lee Y.S., Lee Y.S. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 2004, 340:99-109.
37. Desmarchelier C., Dahlhoff C., Keller S., Sailer M., Jahreis G., Daniel H. C57Bl/6 N mice on a western diet display reduced intestinal and hepatic cholesterol levels despite a plasma hypercholesterolemia. BMC Genomics 2012, 13:84.